Xoma Royalty Corp (XOMAP) Stock Price & Analysis
Xoma Royalty Corp (XOMAP) rose 0.00% to USD 25.52 as of June 10, 2026 at 10:47 UTC, according to Nexqual real-time market data.
XOMAP last closed at USD 25.52; the session ranged USD 25.52–25.52 on volume of 409 shares. Market capitalization is —, with a 52-week range of USD 25.14–30 (NGM). Source: Nexqual, June 10, 2026 at 10:47 UTC.
Key Statistics (as of June 10, 2026 at 10:47 UTC)
| Price | USD 25.52 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 25.52 |
| Open | USD 25.52 |
| Day Range | USD 25.52 – 25.52 |
| 52-Week Range | USD 25.14 – 30 |
| Volume | 409 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (XOMAP)
Nexqual's technical model rates XOMAP "SELL" based on 2 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 10:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.92 (neutral) |
| vs SMA50 | Below (USD 25.73) |
| MACD | -0.02 (negative) |
Analyst Ratings (XOMAP)
Wall Street analysts rate XOMAP "None", per Nexqual as of June 10, 2026 at 10:47 UTC.
| Consensus Rating | None |
|---|
Earnings (XOMAP)
| Revenue Estimate | $13.91M |
|---|
Source: Nexqual, June 10, 2026 at 10:47 UTC.
Financials & Fundamentals (XOMAP)
| Total Revenue | $48.55M |
|---|---|
| Revenue Growth (YoY) | -22.60% |
| Gross Margin | +99.04% |
| Operating Margin | -3.90% |
| Profit Margin | +69.63% |
| ROE | +34.23% |
| Debt / Equity | 110.49 |
| Current Ratio | 3.59 |
| Total Cash | $86.09M |
| Total Debt | $124.73M |
| Free Cash Flow | $-13.07M |
Source: Nexqual, June 10, 2026 at 10:47 UTC.
Financial Health Score (XOMAP)
Nexqual rates Xoma Royalty Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 10:47 UTC.
| Growth | Strong — Revenue +83% YoY (annual) |
|---|---|
| Profitability | Weak — Operating margin -4% |
| Balance Sheet | Mixed — $86M cash vs $125M debt |
| Cash Flow | Weak — FCF negative: -$13M, burning cash |
| Efficiency | Strong — ROE 34%, ROA 1.3% |
Ownership (XOMAP)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +1.02% |
| Float | 882,011 |
Source: Nexqual, June 10, 2026 at 10:47 UTC.
Leadership (XOMAP)
Xoma Royalty Corp is led by Owen P. Hughes (age 50), CEO & Director, per Nexqual as of June 10, 2026 at 10:47 UTC.
| CEO & Director | Owen P. Hughes (age 50) |
|---|---|
| Chief Financial Officer | Jeffrey Trigilio (age 41) |
Major Backers & Investors (XOMAP)
Notable institutional backers of Xoma Royalty Corp include Gabelli Global Small & Mid Cap Value Trust, according to Nexqual as of June 10, 2026 at 10:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Gabelli Global Small & Mid Cap Value Trust | 1.14% |
Source: Nexqual, June 10, 2026 at 10:47 UTC.
From Xoma Royalty Corp's Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.
- It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
- The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XOMAO | XOMA Royalty Corporation - Depo | USD 25.4 | ▲ 0.2% |
| FBIOP | Fortress Biotech, Inc. - 9.375% | USD 20.2 | ▼ 2.27% |
| OXLCP | Oxford Lane Capital Corp. - 6.2 | USD 25.01 | ▲ 0% |
| ADAMM | Adamas Trust, Inc. - 7.875% Ser | USD 25.25 | ▼ 0.08% |
| STRRP | Star Equity Holdings, Inc. - 10 | USD 9.7 | ▼ 0.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:47 UTC. This page is informational and not investment advice.